BioCentury
ARTICLE | Clinical News

KHK7580: Phase IIb started

September 15, 2014 7:00 AM UTC

Kyowa began a double-blind, placebo-controlled, Japanese Phase IIb trial to compare 3 dose levels of oral KHK7580 vs. cinacalcet for 3 weeks in about 150 patients with hyperparathyroidism receiving hemodialysis. Kyowa has rights to co-develop and co-market the product from Mitsubishi under a 2008 deal ...